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Abstract: Methamphetamine and its metabolite amphetamine are frequently abused drugs.
Whether obtained legally or from clandestine laboratories it is of relevance to determine the chiral
makeup of these drugs for investigative purpose. Although urine and oral fluid matrices are
commonly offered, less available to independent laboratories are techniques to verify dextro (D-) or
levo (L-) (meth)amphetamine from human K2EDTA plasma. This paper outlines the development
and validation of a method that includes the addition of internal standard and a two-step liquidliquid extraction to remove the analytes from human K2EDTA plasma by triple quadrupole mass
spectrometry (LC-MS/MS). The assay was validated according to the United States Food and Drug
Administration and College of American Pathologists guidelines, including assessment of the
following parameters in plasma validation samples: linear range, limit of detection, lower limit of
quantitation, matrix effects, inter- and intra-day assay precision and accuracy, carry over, linearity
of dilution, matrix effects and stability. The outcome is a validated and reliable method for the
determination of D- and L- isomer concentration of meth(amphetamine) human plasma samples
that can be easily adopted by independent clinical laboratories.
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1. Introduction
With the rising recognition that drugs of abuse increased during the COVID-19
pandemic [1], independent clinical laboratories are called upon, now more than ever, to
offer testing solutions for diagnostic and investigative purpose. Methamphetamine is a
central nervous system (CNS) stimulant whose prevalence has shown significant increase
in (mis)use during recent years [2-4]. Importantly, methamphetamine and its metabolite
amphetamine exist as two enantiomeric forms, dextro (D-) or levo (L-), which produce
radically different effects on the CNS [5]. Aside from the potential use disorder from the
dopamine response that (meth)amphetamine asserts [5], therapeutic doses of each
enantiomer are commonly prescribed for ADHD, narcolepsy, and severe obesity [6,7].
Furthermore, the L-enantiomer is an effective vasoconstrictor used in the over-thecounter formulation of Vicks Vapor Inhaler [6]. This can be problematic when
determining the source of (meth)amphetamine in patient samples that can be easily
adulterated.
Although liquid chromatography tandem mass spectrometry (LC-MS/MS) assays
that detect (meth)amphetamine from human urine or oral fluid matrices are
commonplace, specificity of D- and L- isomers can be methodologically challenging [8-
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10]. And although human blood plasms LC-MS/MS assays that identify
(meth)amphetamine have been deployed [11], less available are plasma assays for
accurate enantiomeric delineation for independent clinical laboratories. Accordingly, this
study describes a validated laboratory developed LC-MS/MS assay to quantify the
enantiomeric forms of (meth)amphetamine) in human blood plasma samples. The assay
was developed in parallel with an assay for 63 electro spray (ES) positive analytes that
reflected identify D- and L- forms of (meth)amphetamine [12]. The result is a human blood
plasma assay that provides an accurate quantitative view of on-board D- and Lenantiomeric (meth)amphetamine in the blood stream for the independent clinical
laboratory.
2. Materials and Methods
2.1. Reagents and Standards
All analyte stock solutions at 1 mg/mL concentrations and deuterated internal
standards at 100 µ g/mL were purchased from Cerilliant Corporation (Round Rock, TX,
USA). All organic solvents including methanol, acetonitrile, formic acid (88%),
dichloromethane, 2 propanol and ethyl acetate were obtained from Fisher Scientific
(Pittsburgh, PA, USA). Blood plasm was collected with the VACUETTE® K2 DTA Blood
Collection Tube.
2.2. Mobile Phase and Extraction Solutions
A D- and L- mobile phase (MPDL) solution was created by adding ~993.2 mL of
methanol to a 1L bottle. Then using a pipettor, 5 mL of type I clinical grade water, 1.5 mL
of acetic acid, and 0.3 mL of ammonium hydroxide were added. This solution can be kept
at room temperature for up to 1 year. Mobile phase A was prepared by adding 974 mL of
LCMS grade deionized water, 25 mL of methanol, and 1 mL of 88% formic acid to a clean
1 L reagent bottle which was capped and mixed well. This solution can be stored at room
temperature for up to 2 weeks. Mobile phase B was prepared by adding equal parts
methanol and acetonitrile to a clean reagent bottle which was capped and mixed well.
This solution can be kept at room temperature for up to 1 year. Extraction solution 1 (ES1)
was created with 50% dichloromethane and 50% 2-propanol by using a graduated
cylinder under a fume hood. Equal volumes of dichloromethane and 2-propanol were
added to a clean reagent bottle which was capped and mixed well. Extraction solution 2
(ES2) was created with 50% dichloromethane and 50% ethyl acetate by using a graduated
cylinder under a fume hood. Equal volumes of dichloromethane and ethyl acetate were
added to a clean reagent bottle which was capped and mixed well. ES1 and ES2 can be
kept at room temperature for up to 1 year.
2.3. Standard Preparation
An 8000 ng/mL stock solution was made by combining analyte stock controls and
diluting it with mobile phase A (MPA). In contrast, D- and L- amphetamine and
methamphetamine were added in an amount to make a 4000 ng/mL stock of each isomer
so that combined they would produce an 8000 ng/mL solution of total amphetamine and
methamphetamine. This means that the range of the D- and L- standard curve (SC) is from
2.5 to 1000 ng/mL (half the concentration). The resulting stock standard was diluted with
MPA to produce the SC. Concentrations were 8000 (undiluted), 4000, 2000, 1000 400, 200,
100, 40, 20, 10, 4 and 2 ng/mL. The assay quality controls (QCs) were made similarly; first
making a 7200 ng/mL spiking solution in MPA then diluting to 3200, 2400, 300, 60, 12, and
2 ng/mL. The D- and L- amphetamine and methamphetamine QCs were made at half
concentrations and these solutions were stored at the concentrations above. During
preparation the standards and quality controls were combined 1 part standard and 3 parts
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plasma to make a 250 µ l sample volume. The final D- and L- SC and QC concentrations
were QC: 1000, 500, 250, 125, 50, 25, 12.5, 5, 2.5, 0.5 and 0.25 ng/ml and QC: 900, 400, 300,
37.5, 7.5, 1.5, and 0.25 ng/ml.
The internal standard working solution (ISWS) for the P63 assay and D- and L- assay
was made by filling a 100 mL graduated cylinder to the 50 mL mark with 10% methanol
in water and adding 250 µ L of each of the internal standards listed above. The volume
was brought to 100 mL with an additional 10% methanol producing a concentration of
250 ng/mL.
2.4. Instrumentation
The liquid chromatography components of the LC-MS/MS system consisted of a
model CBM-20A controller, 2 model Prominence LC-20AD pumps, a model DGU-20A5
degasser and a model SIL-20AC autosampler all obtained from (Shimadzu, Columbia
MD, USA, based in Kyoto, Japan). The mass spectrometer used was a SCIEX API 4000 and
the acquisition software was Analyst, v 1.5.2, build 5704 (Framingham, MA, USA).
Nitrogen was obtained using a Peak ABN2ZA gas generator (Peak Scientific, Billerica,
MA, USA). Reagents were weighed on a Mettler Toledo MX5 analytical micro balance
(Fisher Scientific, Pittsburgh, PA, USA). Samples were dried on a TurboVap® LV (Uppsala,
Sweden). Samples were vortexed on a Fisherbrand 120 multitube vortex. The analytical
column was an Astec CHIROBIOTIC® V2 5.0 µ m (2.1mm x 25 cm column) Catalog #
15020AST SUPLECO® , (Bellefonte, PA, USA).
2.5. Analyte Optimization
Individual analytes and internal standards were optimized by using T-infusion with
50%B mobile phase and tuning for declustering potential (DP), entrance potential (EP),
collision energy (CE) and exit potential (CXP) at a flow rate of 0.7 mL/min. The two most
abundant fragments were selected for monitoring using multiple reaction monitoring
(MRM).
2.6. Sample Preparation and Procedures
The samples, standards and QC were extracted using two liquid-liquid extractions
with 1:1 dichloromethane (DCM): isopropyl alcohol (IPA) and 1:1 DCM: ethyl acetate
(EtAc). They were combined, dried, reconstituted with 1:1 methanol (MeOH): water and
combined with mobile phase A for separation of the initial 63 analytes. Sample
preparation for D- and L- analysis by LC-MS/MS involved transferring 50 µ L of the
already extracted standards, QC, and any samples of interest to a new plate. Then 450 µ L
of MPDL was added to each well and mixed with a multichannel pipette, the plate was
covered with a plate mat and analyzed for the D- and L- isomers of amphetamine and
methamphetamine using the listed chiral column. The LC-MS/MS conditions and
separation parameters are presented in Table 1 and Table 2.
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Table 1. LC-MS/MS conditions for human blood plasma sample analysis.

D- and LScan Type:

MRM

Ion source:

Turbo spray

Probe position:

X=5.00, Y=5.2

Polarity:

Positive

Run duration:

11 min

Settling time (msec):

0

Pause time (msec):

7.007 msec

Curtain gas:

35

CAD1 gas:

4

2

ISV (V):

5000

Temperature (°C):

500

Ion Source Gas 1 (GS 1):

50

Ion Source Gas 2 (GS 2):

50

Q1/Q3 resolution:

unit/unit

CEM (V):

2600

3

1

Collision Gas (CAD)

2

Ion Source Voltage (ISV)

3

Channel Electron Multiplier (CEM)

Table 2. Inlet settings for human blood plasma D- and L- assay.

Inlet Settings

D- and L- Assay

Analytical Column

Supelco Astek Chirobiotic V 250 x 2.1 mm, 5 µ m

Guard Cartridge

None

Sample Temperature

15 ± 5.0°C

Column Temperature

30.0 ± 5.0°C

Mobile Phase A

Water:Acetic Acid:Ammonium Hydroxide: Methanol 5:1:0.3:993.5

Mobile Phase B

N/A

Needle Rinse

Water:Acetic Acid:Ammonium Hydroxide: Methanol 5:1:0.3:993.5

Flow Rate

0.3 mL/min

Injection Volume

10 μL

Run Time

11 min

3. Materials and Methods
3.1. Matrix Lot-to-Lot Comparison
Individual lots of human plasma differ according to a person’s overall health and
collection efficiency [13]. A single lot of plasma is not enough to demonstrate the
ruggedness of the assay system when such variability in the matrix exists [13]. Due to this,
and in accordance with current CAP standards, a minimum of 10 lots of human matrix
were collected from drug-free donors. These plasma samples were spiked at a low-level
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concentration with each analyte. These samples were prepared, extracted, and run as
described above. The responses were calculated and the analyte to internal standard (IS)
ratio and %CV is shown in Table 3.
Table 3. Matrix effects fortified with QC material to a concentration of 75 or 37.5 ng/mL and the
%CV determined of the analyte/IS area ratio

Mean

Matrix Comparison

Drug / Metabolite

Analyte/IS Ratio

%CV Analyte/IS ratio

D-Amphetamine
L-Amphetamine
D-Methamphetamine
L-Methamphetamine

0.159
0.17
0.376
0.433

2.96
3.26
4.22
4.48

3.2. Analytical Measurement Range
The analytical measurement range (AMR) of the assay refers to the concentration
range that the assay is validated within and is determined by running a series of
calibration curve standards covering a concentration range that encompass the
concentration of analyte expected to find in patient samples [14]. The limits of the AMR
were bounded by the lower limit of quantitation (LLOQ) and the upper limit of
quantitation (ULOQ). The dynamic range may be described by a linear or quadratic fit
[15, 16]. Calibration curves were created using a minimum of six non-zero calibration
points. To be accepted as the AMR, all points describing the calibration curve must pass
within ± 20% of the nominal concentration [14]. Furthermore, the correlation coefficient
(R2) for the calibration curve must be ≥ 0.99, or R should be ≥0.98 to be acceptable [17, 18].
3.3. Sensitivity
The sensitivity of the assay system refers to the ability to reliably produce a signal
throughout the entire calibration range, but specifically at the low-end of the calibration
curve (the lower limit of quantitation, LLOQ) [19]. In hyphenated mass spectrometry
assays, a signal that produces a signal to noise ratio (S/N) of ≥10 is considered valid for
the LLOQ of an assay system [20]. Further, a S/N ratio of ≥5 is considered clear enough for
the limit of detection. We test the sensitivity of the assay system by injecting six replicates
of the LLOQ over three days and evaluating the resulting analytical determinations.
Standard acceptance criteria of ±20% of nominal concentration apply.
3.4. Intra-day Precision and Accuracy
Intra-day precision and accuracy were determined using six replicates of each of
three QC sample determinations and LLOQ from across at least three validation runs.
Concentrations of the QC samples ranged across the curve, with the low QC set at
approximately 3 times the LLOQ or less, the mid QC near the mid-range of the linear
range of the curve, and the high QC set at 80-90% of the ULOQ. Percent accuracy and
precision was determined for each individual measurement. To be accepted, the precision
and accuracy for the replicate determinations must be ≤20% at each level.
3.5. Inter-day Precision and Accuracy
Inter-day precision and accuracy were determined using all replicates of each of three
quality control (QC low, QC mid, and QC high) and LLOQ sample determinations from
the analytical runs performed on 3 separate days. Concentrations of the QC samples
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ranged across the curve, with the low QC set around 3 times the LLOQ, the mid QC near
the middle of the linear range, and the high QC set at 80-90% of the ULOQ. To be accepted,
the precision and accuracy for the replicate determinations must be ≤20% at each level.
3.6. Exogenous Interfering Substances
Drugs that are known or suspected of interfering with similar bioanalytical systems
should be evaluated to ensure that they do not suppress ionization or cause false-positive
results for a given analyte [21, 22]. The following medications were evaluated: over-thecounter mix, acetaminophen, ibuprofen, pseudoephedrine, caffeine, and naproxen. The
following individual analytes were also tested: salicylic acid, phenylephrine,
phentermine, diphenhydramine, and dextromethorphan. A high concentration of the
possible interfering drug (typically 2,000 ng/mL or greater) was spiked into a low QC
sample (15 – 75 ng/mL low QC). Acceptance criteria for a substance to be deemed as noninterfering is that the quantitated value for the low QC should be within ± 20% of the
nominal value [21]. Furthermore, the spiked substance should not cause a false-positive
or a false-negative result.
3.7. Partial Volumes and Dilutions
A spiked solution was created at a concentration above the ULOQ in this case 4000
ng/mL. The sample was run at discrete dilutions 1:5, 1:10, 1:20, and 1:50. Concentration
determinations for all dilutions should be within ± 20% of the nominal value following
correction for the dilution factor [23, 24]. More recent literature suggests that the signal to
noise ratio of both the quantification trace and the qualifying ion trace be 3-10 [25]. On
occasion, an analyte will not have a quantifying ion that passes this criterion while still
permitting the quantification trace to remain in a meaningful range. These instances
should be documented in the laboratory SOP or validation report.
3.8. Carryover
Carryover is the presence of an analyte in a blank injection following a positive
injection, resulting in a false-positive sample [26]. The injection needle should be washed
in-between samples with a needle wash solution that is intended to remove contamination
from the surface of the needle. The efficiency of this process is monitored during
validation by assessing carryover in the following manner. Samples are injected in the
following sequence: high QC, wash, high QC, wash, high QC, wash. Peak areas are
integrated for both the analyte and internal standard. Peak area in the wash solutions
should be 0.1 % or less of that found in the high QC standard. In addition, the mean of the
peak area in the three wash solutions following the high QC replicates should be less than
20% of the LLOQ being used for the assay [27].
3.9. Additives and Clinical Conditions
Certain anticoagulants and slightly different matrices (plasma versus serum) can
affect the performance of some assays. This is also true for conditions causing hemolytic,
lipemic and icteric (high bilirubin) samples. Accordingly, we investigated these potential
issues by comparing plasma with different anticoagulants including serum, plasma
containing hemolyzed RBC, lipemic, and icteric plasma.
4. Results
4.1. Inter-day Average Back Calculated Calibration Standards
Table 4 shows the range of standard curves of the combined Amphetamine and the
individual D- and L- analytes and the correlation information. D- and L- curve

Brian Robbins et al.

7 of 12

concentrations were half the above concentration ranging from 0.25 (neg) to 1000 ng/mL.
Mean R values were all at least 0.99 indicating good fit to the data.
Table 4. Statistical analysis for each analyte standard curve over three assays.

Drug / Metabolite

Curve
Range
(ng/mL)

Mean R

RSD

Mean Slope

SD Slope

N

Fit

D-Amphetamine

2.5-1000

0.9998

0.00006

0.0042

0.0003

3.0000

Quadratic

L-Amphetamine

2.5-1000

0.9999

0.00012

0.0047

0.0003

3.0000

Quadratic

D-Methamphetamine

2.5-1000

0.9998

0.00006

0.0105

0.0011

3.0000

Quadratic

L-Methamphetamine

2.5-1000

0.9995

0.00010

0.0117

0.0018

3.0000

Quadratic

4.2. Accuracy and Precision, LLOQ
Six replicates of each validation level were run over at least three days. The D- and
L- assay individually had an LLOQ of 2.5 ng/mL with a QC low of 7.5 ng/mL, a QC mid
of 300 ng/mL and a high QC of 900 ng/mL. Tables 5-6 indicate mean, inter-assay and intraassay statistic variability were all below 20%.
Table 5. Inter-assay means and standard deviation (SD) of validation samples
Drug / Metabolite

LLOQ

%CV

%E

LQC

%CV

%E

D-Amphetamine

2.7 ± 0.5

L-Amphetamine

2.8 ± 0.3

D-Methamphetamine

MQC

%CV

%E

HQC

%CV

%E

17.09

9.6

7.8 ± 0.4

6.95

9.9

13.7

7.6 ± 0.6

8.34

3.8

296.3± 7.9

2.67

-1.2

898.6 ± 21.0

2.34

-0.2

0.8

293.4 ± 10.9

3.71

-2.2

866.6 ± 25.7

2.76

-3.7

2.5 ± 0.5

19.48

-0.5

7.5 ± 0.7

9.88

-0.3

286.1 ± 15.2

5.3

-4.6

834.2 ± 59.3

7.11

-7.3

L-Methamphetamine

2.6 ± 0.4

14.24

2.4

7.9 ± 0.6

7.57

5.6

323.4 ± 19.7

6.09

7.8

904.2 ± 59.3

6.56

0.5

Target (ng/ml)

2.5

7.5

300

900

Table 6. Intra-assay precision and accuracy over three (3) days with replicates of six (6) for each
day.
LLOQ
%CV

LQC
%E

%CV

MQC
%E

%CV

HQC
%E

%CV

%E

Drug / Metabolite

MIN

MAX

MIN

MAX

MIN

MAX

MIN

MAX

MIN

MAX

MIN

MAX

MIN

MAX

MIN

MAX

D-Amphetamine

11.76

19.25

0.35

18.33

3.88

8.16

-1.04

7.00

2.25

3.21

-1.69

-0.47

0.64

3.17

-1.83

1.47

L-Amphetamine

8.02

11.63

6.82

17.88

5.76

11.22

-2.39

5.95

2.70

3.85

-4.75

-0.40

1.26

2.39

-6.06

-1.28

D-Methamphetamine 12.53

18.30

-15.24

17.72

2.38

7.66

-10.26

9.72

2.57

6.99

-5.30

-3.42

4.75

8.87

-10.33

-4.35

L-Methamphetamine

15.10

-7.05

18.82

5.36

9.09

1.32

9.75

1.95

5.96

2.29

14.42

4.07

5.21

-3.30

7.35

7.14

4.3. Partial Volumes Accuracy and Precision
An MPA surrogate sample was prepared at 4000 ng/mL. To determine the
concentration of this sample, a dilution must be made so the final concentration would be
less than 2000 ng/mL to get it in the measurement range of the assay. Three replicates of
four dilutions were made and tested: 1) 1:5 target 400 ng/mL; 2) 1:10 with a target of 200
ng/mL; 3) 1:20 with a target of 100 ng/mL; and 4) 1:50 with a target of 40 ng/mL. The results
shown in Table 7 indicate that all analytes can be diluted at all levels.
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Table 7. Dilution study: percent difference from expected with a 4000 (2000) ng/mL standard
diluted as indicated.

Drug / Metabolite

1:5 Dilution

1:10 Dilution

1:20 Dilution

1: 100 Dilution

D-Amphetamine

-2.90

1.44

-8.24

-11.20

L-Amphetamine

-4.40

1.28

-7.28

-9.96

D-Methamphetamine

-2.84

0.32

-9.04

-10.08

L-Methamphetamine

1.44

1.32

-8.16

-8.76

4.4. Room Temperature, Refrigerator, and Freezer Stability
Samples with concentrations of 75, 800, or 1800 ng/mL were prepared in triplicate.
One set was kept at room temperature (RT) overnight, a second set was kept in the
refrigerator (RF) overnight and a third set was kept in the freezer (FZ) overnight. These
validation samples were then run and compared to a triplicate preparation of QC samples
that had been analyzed as normal. Table 8 shows results less than 20% deviation from
expected.
Table 8. Stability testing. QC samples were tested for stability after 3 freeze thaw cycles. They
were also tested overnight at the indicated temperatures. A 3 and 7 day post extraction study were
also performed at 2-8 °C
F/T 3 Cycles

Overnight Stability

Post Preparation Stability

QC

%Diff

RT

4 °C

-20 °C

Init % Diff Nom

%Diff Init Day 3

%Diff Init Day 7

QC 37.5

-4.44

0.82%

0.77%

1.05%

-0.56

-10.46

0.56

QC 400

-1.66

1.17%

0.54%

0.50%

-2.51

-3.97

2.54

QC 37.5

-2.53

0.35%

0.25%

0.45%

-4.41

-4.03

4.51

QC 400

-0.09

0.94%

0.44%

0.43%

-4.10

-2.36

4.19

QC 37.5

1.12

1.86%

1.19%

1.59%

-1.24

9.71

1.25

QC 400

-1.15

1.00%

1.06%

1.76%

-6.30

5.44

6.50

QC 37.5

4.13

1.77%

1.08%

2.24%

8.76

5.16

-8.39

4.5. Freeze-Thaw (FT) Stability
Validation samples with concentrations of 75, 800 or 1800 ng/mL were frozen at -20
°C and thawed in sequence with samples taken after each FT cycle for a maximum of 3
cycles. These validation samples were analyzed in triplicate and compared to a triplicate
preparation of validation samples that had not been subjected to this FT cycle. The
experimental results showed all meeting acceptance criteria.
4.6. Stability in Matrix
A series of triplicate samples were analyzed over 7 days for stability at room
temperature, 4 °C and -20 °C. The results indicated that all analytes were stable for at least
7 days refrigerated and frozen. The analytes were stable at room temperature for 24h
4.7. Post Preperation Stability
A stability experiment was performed where samples were stored in the instrument
(3 day) or refrigerator (7 day) and re-injected after 3 and 7 days. All samples were within
20% of the initial results.
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4.8. Matrix Recovery and Matrix Effects
Table 3 indicates the effect of 10 different matrix lots tested by using a series of 37.5
ng/mL samples prepared in water, MPA and 10 different matrices. The results were
acceptable with less than 20% CV across oral fluid, water and MPA meeting acceptance
criteria. This is likely due to dilution in 1.5 mL Quantisal extraction buffer before
extraction.
4.9. Selectivity
Multiple drugs that might have a potential for interfering with the assay analytes
were run in the assay. Samples of 500 µ L of 37.5 ng/mL QC were placed in a series of tubes
to be run in triplicate. To the first set 50 µ L of MeOH was added to act as the control. To
the remaining tubes 50 µ L of sample containing dextromethorphan, diphenhydramine,
phenylephrine, salicylic acid, or combo (includes acetaminophen, caffeine,
chlorpheniramine, ibuprofen, naproxen, and pseudoephedrine). These solutions were
obtained from Cerilliant Corporation and were at a concentration of 1 mg/mL each except
for the over-the-counter mix which was 100 µ g/mL. Each solution was diluted to 20 µ g/mL
in methanol and this solution was used to spike samples as indicated above. Table 9 shows
the results from this study. All samples met the acceptance criteria.
Table 9. Concomitant medications: The indicated medications prepared in methanol were spiked
into a QC 37.5 standard and measured. The data indicates percent difference from a QC standard
spiked with blank methanol at the same volume as the drug standards.

Percent Difference from MEOH Spike
Drug / Metabolite

Dextromethorphan

Phenylephrine

Diphenhydramine

Salicylic
Acid

Phentermine

OTC
Mix

D-Amphetamine

9.31

0.76

1.79

-3.35

-1.83

-0.76

L-Amphetamine

6.38

1.51

2.18

-2.67

-0.18

-0.84

D-Methamphetamine

4.69

-1.29

-0.62

-7.20

-4.21

-1.55

L-Methamphetamine

10.41

-1.27

5.14

-2.32

-0.71

3.70

4.10. Additives and Clinical Conditions
Samples in triplicate at 37.5 ng/m were compared. These included serum defibrinated
plasma, EDTA, and heparin. Clinical considerations included hemolytic, lipemic, and
icteric samples. No deviations of more than 15% was observed and only serum was more
than 10% (Table 10). This indicates that none of these conditions adversely affects the
measurement of these analytes.
Table 10. Alternate matrices, anti-coagulants, and disease states

Drug / Metabolite
D-Amphetamine
L-Amphetamine
D-Methamphetamine
L-Methamphetamine

% Diff from Target
Defibrinated EDTA
-4.07
-2.88
-4.52
-4.60

-3.78
-2.55
-7.00
-5.40

Heparin

Serum

Hemolyzed

Lipemic

-5.54
-5.04
-9.06
-6.61

-4.89
-5.58
-12.28
-11.16

-4.09
-5.08
-10.18
-10.70

-4.82
-4.94
-7.43
-8.05

Icteric 2
-3.14
-3.54
-7.04
-7.37

Icteric 20
-6.39
-6.13
-8.64
-7.15
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5. Discussion
Urine and oral fluid are commonly preferred matrices for drug toxicological
testing. On occasion, medical providers deem it medically necessary to order toxicology
testing on a blood sample. Accordingly, this study describes a validated laboratory
developed LC-MS/MS assay to quantify the enantiomeric forms of (meth)amphetamine)
in human blood plasma samples. The utility of this assay is its concomitant use when
(meth)amphetamine is detected in a broader confirmation panel in order to determine if
the positive result was from the legal or illicit form of (meth)amphetamine. This assay
removes the plausible deniability of illicit (meth)amphetamine use as an artifact of
decongestant use or a false-positive due to prescriptive forms of amphetamine.
All analytes were well-behaved during development, providing a meaningful
analytical measurement range, acceptable intra-day and inter-day precision and
accuracy, specificity for the target analytes, and the assay demonstrated acceptable
stability that allows for a reasonable laboratory workflow. The most important aspect of
this assay was its specificity. It can reliably and definitively differentiate between the
isomeric forms of (meth)amphetamine, as well as common decongestants and weight
loss medication. Phentermine is a positional isomer of methamphetamine that
laboratories need to ensure does not interfere in methamphetamine confirmation [28].
As a positional isomer, it shares a molecular weight and fragment pattern nearly
indiscernible from methamphetamine by many LC-MS/MS methods. Chromatographic
separation saw phentermine elute at 4.21 minutes, while methamphetamine eluted at
6.06 for the D- isomer and 6.58 minutes for the L-isomer. Furthermore, phentermine only
shared the qualifying ion signal with methamphetamine, but not the quantifying ion.
Since the peaks were temporally separated by 1.85 minutes, phentermine shows no
interference in the MRM window that is used for D- or L- methamphetamine.
Physicians may choose blood as a matrix for toxicologic testing for numerous
reasons [29]. While urine is the most frequently used biologic matrix, drug
concentrations in urine do not necessarily reflect circulating concentrations of drugs.
Oral fluids offer a secondary biological matrix, but there is poor penetration of certain
drugs and their metabolites into the oral fluid compartment therefore limiting the utility
of the assay [30]. Further, some individuals have difficulty providing a urine or oral
fluid specimen and blood is consequently selected as a suitable sample for toxicology
testing. The attractiveness of blood is that the drug levels detected are biologically
available and both active and inactive metabolites are detectable, unlike in oral fluid.
Likewise, unlike urine and oral fluid, it is exquisitely difficult to tamper with or
adulterate blood samples [29].
This assay is reliable, reproducible, and removes plausible deniability from drug
confirmations for D- and L- (meth)amphetamine in blood plasma samples. It provides a
fully quantitative analysis of each of the stereoisomers of two clinically significant
stimulants—methamphetamine and its metabolite amphetamine, and it cleanly
separates these analytical targets from interfering substances. The sensitivity of the assay
is tremendous considering that this assay uses an older instrument (API SCIEX 4000)
and can be meaningful for many clinical laboratories looking to perform drug
confirmation studies for (meth)amphetamine.
6. Conclusion
The determination of prescription medications and illicit substances in human blood
plasma is critical, notably where potential adulteration is a concern. Moreover, human
blood plasma methods to quantitatively detect the enantiomeric forms of
(meth)amphetamine has medical compliance and treatment implications [31], and
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warrants de-centralized offerings by independent clinical laboratories, especially in rural
regions where (meth)amphetamine (mis)use is on the rise [32]. This paper describes a
method to determine the D- and L- isomers of (meth)amphetamine using an older, less
sensitive instrument (API SCIEX 4000) by using a liquid-liquid extraction method,
concentration of the samples with a nitrogen dry-down, and a resuspension step. The
method was validated in accordance with the US Food and Drug Administration and
College of American Pathologists with an LLOQ of 2.5 ng/mL and ULOQ of 1000 ng/mL.
The novelty of this work is a sensitive method for the determination of the D- and Lisomers of (meth)amphetamine from an extract used for determination of 63 analytes from
human K2EDTA plasma. The assay has good precision and accuracy and would a suitable
addition to any clinical laboratory seeking confirmation of the enantiomeric forms of
(meth)amphetamine following immunoassay or GC/MS positive results for
methamphetamine or its metabolite amphetamine.
Data Availability Statement: Harvard Dataverse https://doi.org/10.7910/DVN/TBEWWE
Conflicts of Interest: The authors declare no conflict of interest.
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